OSR Holdings, Inc. 8-K

What Happened

• On April 29, 2026, OSR Holdings, Inc. (OSRH), together with its subsidiary Vaximm AG, entered into a Global Exclusive License Agreement with BCM Europe AG (BCME), the company’s largest shareholder.
• Under the agreement BCME gets exclusive worldwide rights to develop, fund, register and commercialize VXM01, an oral DNA‑based cancer immunotherapy platform. BCME will also be able to sublicense the program. The Board approved the related‑party deal after receiving an independent fairness opinion from Avance Life Sciences AG.

Key Details

• Milestones & royalties: BCME may pay up to $815,000,000 in aggregate milestone payments tied to clinical, regulatory and commercial milestones; a royalty pass‑through will remit royalties from any ultimate licensee to OSR after certain returns to BCME are recovered.
• Equity put option: OSR may require BCME to buy up to $15,000,000 of OSR common stock at $10.00 per share during a specified exercise period.
• IP/asset transaction: The parties agreed to negotiate a separate asset purchase (pending definitive docs) for OSR to acquire certain VXM01 IP from Vaximm for $30,000,000.
• Security for milestones: BCME and affiliates pledged 9,974,728 OSR shares as collateral to secure milestone payments; the pledge becomes effective February 15, 2028 due to existing lock‑up restrictions and creates a first‑priority security interest.

Why It Matters

• The deal shifts development, regulatory and commercialization costs and responsibilities for VXM01 to BCME while preserving upside for OSR via milestone payments, royalties and an equity put option — providing potential non‑dilutive near‑term value and future revenue streams if milestones are met.
• Because BCME is OSR’s largest shareholder and the transaction includes share collateral and an equity put option, investors should note the related‑party nature of the agreement and the pledged shares that secure BCME’s payment obligations.
• Pending the separate IP purchase and future milestone/royalty outcomes, the transaction materially changes how VXM01 will be advanced and monetized compared with in‑house development.